A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)

Trial Profile

A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Imatinib (Primary) ; Hydroxycarbamide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Jun 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-002600-41).
    • 16 Jun 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-002600-41).
    • 13 May 2011 Planned end date added 1 Aug 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top